Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Migration, Crosslink

📖

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-epigenetic-reprogrammi

📖 Wiki Page

therapeutic1113 wordssynced 2026-04-02

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Founded</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Headquarters</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td class="label">Founders</td>
<td>Brian Armstrong, Blake Byers</td>
</tr>
<tr>
<td class="label">CEO</td>
<td>Brian Armstrong</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>$400M+ Series B (December 2023)</td>
</tr>
<tr>
<td class="label">Pipeline</td>
<td>T cell rejuvenation, liver regeneration, CNS programs (preclinical)</td>
</tr>
<tr>
<td class="label">Factor Combination</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">OSK only</td>
<td>Partial rejuvenation</td>
</tr>
<tr>
<td class="label">OSK + c-MYC</td>
<td>Enhanced proliferation</td>
</tr>
<tr>
<td class="label">Full OSKM</td>
<td>Full pluripotency</td>
</tr>
<tr>
<td class="label">Novel cocktails</td>
<td>Optimized rejuvenation</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">Altos Labs</td>
<td>Broad rejuvenation</td>
</tr>
<tr>
<td class="label">Calico (Alphabet)</td>
<td>Aging + longevity</td>
</tr>
<tr>
<td class="label">Retro Biosciences</t

...

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Founded</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Headquarters</td>
<td>South San Francisco, CA</td>
</tr>
<tr>
<td class="label">Founders</td>
<td>Brian Armstrong, Blake Byers</td>
</tr>
<tr>
<td class="label">CEO</td>
<td>Brian Armstrong</td>
</tr>
<tr>
<td class="label">Funding</td>
<td>$400M+ Series B (December 2023)</td>
</tr>
<tr>
<td class="label">Pipeline</td>
<td>T cell rejuvenation, liver regeneration, CNS programs (preclinical)</td>
</tr>
<tr>
<td class="label">Factor Combination</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">OSK only</td>
<td>Partial rejuvenation</td>
</tr>
<tr>
<td class="label">OSK + c-MYC</td>
<td>Enhanced proliferation</td>
</tr>
<tr>
<td class="label">Full OSKM</td>
<td>Full pluripotency</td>
</tr>
<tr>
<td class="label">Novel cocktails</td>
<td>Optimized rejuvenation</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">Altos Labs</td>
<td>Broad rejuvenation</td>
</tr>
<tr>
<td class="label">Calico (Alphabet)</td>
<td>Aging + longevity</td>
</tr>
<tr>
<td class="label">Retro Biosciences</td>
<td>Cellular reprogramming</td>
</tr>
<tr>
<td class="label">Life Biosciences</td>
<td>Epigenetic reprogramming</td>
</tr>
<tr>
<td class="label">Shift Bioscience</td>
<td>Controlled reprogramming</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Epigenetic Reprogramming</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Reverse epigenetic age</td>
</tr>
<tr>
<td class="label">Target</td>
<td>All cell types</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Oncogenic (managed)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical</td>
</tr>
</table>

Epigenetic reprogramming refers to the process of resetting epigenetic marks—[DNA methylation](/entities/dna-methylation) patterns, [histone modifications](/entities/histone-modifications), and chromatin accessibility—to a more youthful state without necessarily converting cells to pluripotent stem cells. This approach has emerged as one of the most promising anti-aging and neurodegeneration therapeutic strategies, with several companies advancing programs toward clinical translation. [@ocampo2016]

Partial reprogramming using the Yamanaka factors (OCT4, SOX2, KLF4, c-MYC, or subsets thereof) can reverse epigenetic aging while avoiding the tumorogenic risks associated with full pluripotency. Research has demonstrated that cyclic or controlled expression of these factors can improve tissue function, reverse age-related transcriptomic changes, and promote regeneration in multiple organ systems including the brain. [@browder2022]

--- [@lu2020]

NewLimit: Company Profile

NewLimit is a biotechnology company founded in 2022 by Brian Armstrong (co-founder and CEO of Coinbase) and Blake Byers (genomics scientist formerly at Google). The company is focused on developing epigenetic reprogramming therapies to treat age-related diseases, with an initial focus on immune senescence and potential applications in neurodegeneration. [@chen2021]

Key Facts

Approach

NewLimit's approach combines:

Epigenetic target identification — Using machine learning to identify key epigenetic regulators of aging

Partial reprogramming — Using optimized combinations of Yamanaka factors or novel factor cocktails

Delivery technologies — Engineered viral vectors and non-viral approaches for tissue-specific delivery

Controlled expression — Pulsed or cyclic delivery to avoid oncogenic risk

Pipeline

T cell rejuvenation — Lead program targeting age-related immune decline. Preclinical data shows restoration of naive T cell populations and improved function in aged mice.
Liver regeneration — Partnered with external labs for liver disease applications
CNS/neurodegeneration — Early discovery programs for Alzheimer's and Parkinson's disease

Technology Platform

NewLimit has developed:

Epigenetic aging sensors — Reporter systems to measure reprogramming progress
Factor optimization — Engineered versions of OSK with improved safety profiles
Delivery systems — Novel AAV variants and lipid nanoparticles for tissue targeting

Epigenetic Reprogramming Science

Molecular Mechanism

The Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) are transcription factors that can reset somatic cells to pluripotency. However, partial reprogramming involves expressing these factors transiently or using subsets to achieve rejuvenation without full dedifferentiation.

Mermaid diagram (expand to render)

Key Research Findings

Izpisua Belmonte group (2016) — First demonstration that cyclic expression of OSK could reverse epigenetic aging in mice without tumors [1](https://doi.org/10.1016/j.cell.2016.11.052)

Horvath and colleagues (2023) — Epigenetic clock analysis shows partial reprogramming can reduce biological age by 30-50% in human cells [2](https://doi.org/10.1002/ctm2.1289)

Lu et al. (2020) — In vivo partial reprogramming improved vision and nerve regeneration in mice [3](https://doi.org/10.1038/s41586-020-2415-3)

Chen et al. (2021) — Transient reprogramming reversed age-associated changes in human fibroblasts while maintaining cell identity [4](https://doi.org/10.1038/s41587-021-00935-2)

Gill et al. (2022) — Multi-omic rejuvenation of human cells by maturation phase transient reprogramming [5](https://doi.org/10.1038/s41586-022-04444-2)

OSK vs. Full Yamanaka

Neurodegeneration Applications

Why Epigenetic Reprogramming for AD/PD?

Age is the primary risk factor — Epigenetic aging underlies neuronal vulnerability

[Neurons](/entities/neurons) are post-mitotic — Cannot be replaced, making rejuvenation critical

Glial cells can be targeted — [Microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes) can be reprogrammed

Synaptic function restoration — Epigenetic reset may restore synaptic plasticity

Preclinical Evidence

AD models — OSK expression in 5xFAD mice reduced amyloid pathology and improved cognition
PD models — Partial reprogramming protected dopaminergic neurons in [α-synuclein](/proteins/alpha-synuclein) models
Neuronal regeneration — Axon regeneration enhanced in aged retinal ganglion cells

Challenges for CNS Delivery

[Blood-brain barrier](/entities/blood-brain-barrier) — Requires BBB-crossing vectors (AAV-PHP.eB, AAVrh10, focused ultrasound)

Neuronal targeting — Need cell-type specific promoters

Controlled expression — Pulsed delivery to avoid oncogenicity

Immunogenicity — Viral vector pre-existing antibodies

Competitive Landscape

Other Companies in Epigenetic Reprogramming

Comparison with Senolytics

Epigenetic reprogramming and senolytic approaches represent complementary strategies:

Clinical Outlook

Timeline

2025-2026 — First human trials likely for non-CNS indications (T cell, liver)
2027-2028 — CNS trials possible pending BBB delivery advances
2030+ — Potential disease-modifying therapy for early AD/PD

Regulatory Considerations

FDA has not yet approved reprogramming therapies
Safety concerns around tumorigenicity require careful monitoring
Novel delivery systems may require new regulatory pathways

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

[OSK Reprogramming and Yamanaka Factors in Neurodegeneration](/diseases/neurodegeneration)
[Senolytics and Senescence in Neurodegeneration](/diseases/neurodegeneration)
[Longevity and Rejuvenation Therapies Landscape](/therapeutics/longevity-rejuvenation-therapies)
[Blood-Brain Barrier Biology and Crossing Strategies](/mechanisms/blood-brain-barrier-biology)
AAV Gene Therapy Vectors for CNS

References

[Ocampo et al., In Vivo Amelioration of Age-Associated Traits by Epigenetic Reprogramming (Cell, 2016) (2016)](https://doi.org/10.1016/j.cell.2016.11.052)

[Browder et al., In vivo partial reprogramming alters age-associated molecular changes while protecting cellular identity (Cell Stem Cell, 2022) (2022)](https://doi.org/10.1016/j.stem.2022.06.018)

[Lu et al., Reprogramming to Recover Youthful Epigenetic Information and Restore Vision (Nature, 2020) (2020)](https://doi.org/10.1038/s41586-020-2415-3)

[Chen et al., In vivo partial reprogramming alters age-associated molecular changes while protecting cellular identity (Nature Aging, 2021) (2021)](https://doi.org/10.1038/s41587-021-00935-2)

[Gill et al., Multi-omic rejuvenation of human cells by maturation phase transient reprogramming (Nature, 2022) (2022)](https://doi.org/10.1038/s41586-022-04444-2)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-epigenetic-reprogramming

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-epigenetic-reprogramming
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1a4d75451a51
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-epigenetic-reprogramming'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

559

Outgoing

764

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Overview

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Overview

NewLimit: Company Profile

Key Facts

Approach

Pipeline

Technology Platform

Epigenetic Reprogramming Science

Molecular Mechanism

Key Research Findings

OSK vs. Full Yamanaka

Neurodegeneration Applications

Why Epigenetic Reprogramming for AD/PD?

Preclinical Evidence

Challenges for CNS Delivery

Competitive Landscape

Other Companies in Epigenetic Reprogramming

Comparison with Senolytics

Clinical Outlook

Timeline

Regulatory Considerations

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Overview

Epigenetic Reprogramming and Partial Reprogramming in Neurodegeneration

Overview

NewLimit: Company Profile

Key Facts

Approach

Pipeline

Technology Platform

Epigenetic Reprogramming Science

Molecular Mechanism

Key Research Findings

OSK vs. Full Yamanaka

Neurodegeneration Applications

Why Epigenetic Reprogramming for AD/PD?

Preclinical Evidence

Challenges for CNS Delivery

Competitive Landscape

Other Companies in Epigenetic Reprogramming

Comparison with Senolytics

Clinical Outlook

Timeline

Regulatory Considerations

See Also

External Links

Related Pages

References

Related Hypotheses

Pathway Diagram

💬 Discussion